TapewireFind a company

person · Reporting owner

Pearce Samantha

Disclosed activity across 1 company

Tapewire entity
25585
SEC CIK
0001805688

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Jazz Pharmaceuticals plcJAZZ · Entity 818EVP, Chief Commercial OfficerAugust 05, 2026August 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jazz Pharmaceuticals plc

Report date August 05, 2026 · Filed August 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect47,131 Reported balance After 2026-08-05 transaction · row 1
1 source row

Row 1 · 2026-08-05 · Tax withholding · Disposed 780 · Balance 47,131

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 05, 2026 Filed Aug 7, 2026 22:01 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 780 $261.62 $204,063.60
Disclosure

SEC source: 0001805688-26-000014 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,131

F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Read SEC document
June 30, 2026 Filed Jul 2, 2026 22:27 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 2,527 $237.72 $600,718.44
Disclosure

SEC source: 0001805688-26-000012 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,911

F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:06 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 6,907 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001805688-26-000008 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,907 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vested in 36 equal monthly installments thereafter. The option was fully vested as of March 2, 2024.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:06 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 6,907 $235.41 $1,625,976.87
Disclosure

SEC source: 0001805688-26-000008 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,272

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:06 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 6,907 $109.45 $755,971.15
Disclosure

SEC source: 0001805688-26-000008 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 21:23 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 2,503 $188.69 $472,291.07
Disclosure

SEC source: 0001805688-26-000006 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,272

F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Read SEC document
February 26, 2026 Filed Mar 2, 2026 22:19 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 9,782 $0.00 $0.00
Disclosure

SEC source: 0001805688-26-000004 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,775

F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

Read SEC document
January 16, 2026 Filed Jan 22, 2026 01:17 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 1,599 $171.16 $273,684.84
Disclosure

SEC source: 0001805688-26-000002 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,993

F3 · kind: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.

Read SEC document
January 16, 2026 Filed Jan 22, 2026 01:17 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 3,637 $0.00 $0.00
Disclosure

SEC source: 0001805688-26-000002 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,592

F1 · kind: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.

F2 · balance_after: The Reporting Person acquired 140 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.

Read SEC document
August 05, 2025 Filed Aug 7, 2025 22:06 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 577 $116.10 $66,989.70
Disclosure

SEC source: 0001765581-25-000051 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,815

F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025.

Read SEC document
March 05, 2025 Filed Mar 8, 2025 00:00 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Disposition to issuerOrdinary Shares 1,905 $138.95 $264,699.75
Disclosure

SEC source: 0001765581-25-000029 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,226

F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Read SEC document
February 27, 2025 Filed Mar 4, 2025 00:35 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 5,778 $0.00 $0.00
Disclosure

SEC source: 0001765581-25-000016 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,131

F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026.

Read SEC document
February 27, 2025 Filed Mar 4, 2025 00:35 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 11,941 $0.00 $0.00
Disclosure

SEC source: 0001765581-25-000016 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,353

F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

Read SEC document
January 17, 2025 Filed Jan 22, 2025 23:40 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 1,365 $122.62 $167,376.30
Disclosure

SEC source: 0001805688-25-000003 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,412

F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.

Read SEC document
January 17, 2025 Filed Jan 22, 2025 23:40 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 2,533 $0.00 $0.00
Disclosure

SEC source: 0001805688-25-000003 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,777

F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified.

F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024.

Read SEC document
August 02, 2024 Filed Aug 6, 2024 20:53 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 6,996 $0.00 $0.00
Disclosure

SEC source: 0001765581-24-000072 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,078

F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of August 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

F2 · balance_after: Includes 160 ordinary shares acquired on May 31, 2024 under a Section 423 Employee Stock Purchase Plan.

Read SEC document
March 05, 2024 Filed Mar 8, 2024 02:49 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 2,474 $117.53 $290,769.22
Disclosure

SEC source: 0001765581-24-000035 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,922

F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 00:52 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 5,065 $0.00 $0.00
Disclosure

SEC source: 0001765581-24-000022 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,396

F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

Read SEC document
January 17, 2024 Filed Jan 19, 2024 23:33 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 1,038 $119.13 $123,656.94
Disclosure

SEC source: 0001784606-24-000012 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,331

F2 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.

Read SEC document
January 17, 2024 Filed Jan 19, 2024 23:33 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 2,210 $0.00 $0.00
Disclosure

SEC source: 0001784606-24-000012 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,369

F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified.

Read SEC document
March 05, 2023 Filed Mar 8, 2023 01:54 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Tax withholdingOrdinary Shares 2,020 $142.78 $288,415.60
Disclosure

SEC source: 0001765581-23-000019 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,159

F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

Read SEC document
March 03, 2023 Filed Mar 8, 2023 01:54 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 GrantOrdinary Shares 3,870 $0.00 $0.00
Disclosure

SEC source: 0001765581-23-000019 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,179

F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

Read SEC document
February 02, 2023 Filed Feb 6, 2023 21:26 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 531 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-23-000008 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,907

Underlying: Ordinary Shares · 531 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
February 02, 2023 Filed Feb 6, 2023 21:26 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 531 $157.26 $83,505.06
Disclosure

SEC source: 0001765581-23-000008 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
February 02, 2023 Filed Feb 6, 2023 21:26 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 531 $109.45 $58,117.95
Disclosure

SEC source: 0001765581-23-000008 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 23:43 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 531 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-23-000004 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,438

Underlying: Ordinary Shares · 531 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 23:43 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 531 $159.59 $84,742.29
Disclosure

SEC source: 0001765581-23-000004 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 23:43 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 531 $109.45 $58,117.95
Disclosure

SEC source: 0001765581-23-000004 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
December 13, 2022 Filed Dec 15, 2022 23:29 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 531 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000140 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,969

Underlying: Ordinary Shares · 531 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
December 13, 2022 Filed Dec 15, 2022 23:29 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 531 $155.45 $82,543.95
Disclosure

SEC source: 0001765581-22-000140 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
December 13, 2022 Filed Dec 15, 2022 23:29 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 531 $109.45 $58,117.95
Disclosure

SEC source: 0001765581-22-000140 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
November 10, 2022 Filed Nov 14, 2022 23:16 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 531 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000120 · edgardoc.xml · derivative · entry 6

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Ordinary Shares · 531 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
November 10, 2022 Filed Nov 14, 2022 23:16 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 532 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000120 · edgardoc.xml · derivative · entry 5

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,031

Underlying: Ordinary Shares · 532 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
November 10, 2022 Filed Nov 14, 2022 23:16 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 531 $155.00 $82,305.00
Disclosure

SEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 4

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

Read SEC document
November 10, 2022 Filed Nov 14, 2022 23:16 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 531 $109.45 $58,117.95
Disclosure

SEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 10, 2022 Filed Nov 14, 2022 23:16 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 532 $155.00 $82,460.00
Disclosure

SEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

Read SEC document
November 10, 2022 Filed Nov 14, 2022 23:16 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 532 $109.45 $58,227.40
Disclosure

SEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 02, 2022 Filed Sep 7, 2022 21:12 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 531 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000109 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,563

Underlying: Ordinary Shares · 531 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
September 02, 2022 Filed Sep 7, 2022 21:12 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 531 $156.98 $83,356.38
Disclosure

SEC source: 0001765581-22-000109 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
September 02, 2022 Filed Sep 7, 2022 21:12 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 531 $109.45 $58,117.95
Disclosure

SEC source: 0001765581-22-000109 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:33 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 531 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000075 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,094

Underlying: Ordinary Shares · 531 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:33 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 531 $155.00 $82,305.00
Disclosure

SEC source: 0001765581-22-000075 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:33 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 531 $109.45 $58,117.95
Disclosure

SEC source: 0001765581-22-000075 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 12, 2022 Filed Jul 14, 2022 22:15 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 532 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000071 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,625

Underlying: Ordinary Shares · 532 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
July 12, 2022 Filed Jul 14, 2022 22:15 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 532 $155.00 $82,460.00
Disclosure

SEC source: 0001765581-22-000071 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
July 12, 2022 Filed Jul 14, 2022 22:15 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 532 $109.45 $58,227.40
Disclosure

SEC source: 0001765581-22-000071 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 27, 2022 Filed Jun 29, 2022 21:55 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 8,508 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000065 · edgardoc.xml · derivative · entry 3

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,157

Underlying: Ordinary Shares · 8,508 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Read SEC document
June 27, 2022 Filed Jun 29, 2022 21:55 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 SaleOrdinary Shares 8,508 $155.00 $1,318,740.00
Disclosure

SEC source: 0001765581-22-000065 · edgardoc.xml · nonDerivative · entry 2

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,309

Read SEC document
June 27, 2022 Filed Jun 29, 2022 21:55 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionOrdinary Shares 8,508 $109.45 $931,200.60
Disclosure

SEC source: 0001765581-22-000065 · edgardoc.xml · nonDerivative · entry 1

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,817

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 21:24 UTC Jazz Pharmaceuticals plc JAZZ · Entity 818 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 5,835 $0.00 Strike: $109.45 $0.00
Disclosure

SEC source: 0001765581-22-000063 · edgardoc.xml · derivative · entry 4

Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,665

Underlying: Ordinary Shares · 5,835 shares

Expires 2030-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.